| HOME >> BIOLOGY >> TECHNOLOGY |
John S. Sundy M.D., Ph.D., is Associate Professor of Medicine and Head of the Section of Allergy and Clinical Immunology in the Division of Pulmonary, Allergy and Critical Care Medicine at Duke University Medical Center. Dr. Sundy is Director of the adult allergy training program at Duke, and is Director of rheumatology research at the Duke Clinical Research Institute. He is board certified in the fields of Rheumatology and Allergy/Immunology and is a national leader in the clinical testing of novel therapies for gout. His additional research interests include translational studies in inflammatory diseases such as asthma and allergic rhinitis.
Ikumi Tamai, Ph.D., is Professor of Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan. His research has focused on the relevance of transporters to the efficacy and toxicity of drugs, as well as the pharmacokinetics of drugs and its application to intestinal drug delivery. Recent areas of study include transporters in the lung, uric acid transporters, drug-induced changes in uric acid transporters, species effect on transporters and drug transports related to intestinal absorption and elimination. He has published over 180 original articles mainly related to transporters.
About Ardea Biosciences, Inc.
Ardea Biosciences of Carlsbad, California is a biotechnology company
focused on the discovery and development of small-molecule therapeutics in
virology, oncology and inflammation. The Company has two product candidates
in clinical development and several others in preclinical development.
Ardea's most advanced clinical development candidate is RDEA806, a
non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a P
'/>"/>
| SOURCE Ardea Biosciences, Inc. Copyright©2008 PR Newswire. All rights reserved |